+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Clostridioides difficile Infections (Clostridium difficile Associated Disease) - Pipeline Review, H1 2020

  • ID: 5024735
  • Drug Pipelines
  • April 2020
  • Region: Global
  • 267 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • Absynth Biologics Ltd
  • CSA Biotechnologies LLC
  • Immune Biosolutions Inc
  • Locus Biosciences Inc
  • Otsuka Holdings Co Ltd
  • Scioto Biosciences Inc
  • MORE
Clostridioides difficile Infections (Clostridium difficile Associated Disease) - Pipeline Review, H1 2020

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Clostridioides difficile Infections - Pipeline Review, H1 2020, provides an overview of the Clostridioides difficile Infections (Infectious Disease) pipeline landscape.

Clostridium difficile infections are caused by Clostridium difficile, often called C. difficile or C. diff, a bacterium that can cause symptoms ranging from diarrhea to life-threatening inflammation of the colon. Symptoms of C. diff infection includes watery diarrhea, with abdominal pain or tenderness, loss of appetite, fever, blood or pus in the stool and weight loss. Risk factors are age, surgery of the gastrointestinal (GI) tract, a weakened immune system, kidney disease, use of drugs called proton-pump inhibitors, which lessen stomach acid and use of chemotherapy drugs. This condition may be controlled by the use of medication such as antibiotics and may be prevented by lifestyle modification.

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Clostridioides difficile Infections - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Clostridioides difficile Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Clostridioides difficile Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Clostridioides difficile Infections (Clostridium difficile Associated Disease) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 5, 10, 11, 40, 20 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 4 and 7 molecules, respectively.

Clostridioides difficile Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Clostridioides difficile Infections (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Clostridioides difficile Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Clostridioides difficile Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Clostridioides difficile Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Clostridioides difficile Infections (Infectious Disease)
Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Clostridioides difficile Infections (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Clostridioides difficile Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Absynth Biologics Ltd
  • CSA Biotechnologies LLC
  • Immune Biosolutions Inc
  • Locus Biosciences Inc
  • Otsuka Holdings Co Ltd
  • Scioto Biosciences Inc
  • MORE
  • Introduction
  • Clostridioides difficile Infections (Clostridium difficile Associated Disease) - Overview
  • Clostridioides difficile Infections (Clostridium difficile Associated Disease) - Therapeutics Development
  • Clostridioides difficile Infections (Clostridium difficile Associated Disease) - Therapeutics Assessment
  • Clostridioides difficile Infections (Clostridium difficile Associated Disease) - Companies Involved in Therapeutics Development
  • Clostridioides difficile Infections (Clostridium difficile Associated Disease) - Drug Profiles
  • Clostridioides difficile Infections (Clostridium difficile Associated Disease) - Dormant Projects
  • Clostridioides difficile Infections (Clostridium difficile Associated Disease) - Discontinued Products
  • Clostridioides difficile Infections (Clostridium difficile Associated Disease) - Product Development Milestones
  • Appendix
List of Tables
  • Number of Products under Development for Clostridioides difficile Infections (Clostridium difficile Associated Disease), H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..2), H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..3), H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..2), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..3), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..4), H1 2020
  • Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Clostridioides difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Absynth Biologics Ltd, H1 2020
  • Clostridioides difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Acurx Pharmaceuticals LLC, H1 2020
  • Clostridioides difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Appili Therapeutics Inc, H1 2020
  • Clostridioides difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Artugen Therapeutics Ltd, H1 2020
List of Figures
  • Number of Products under Development for Clostridioides difficile Infections (Clostridium difficile Associated Disease), H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Top 10 Targets, H1 2020
  • Number of Products by Stage and Top 10 Targets, H1 2020
  • Number of Products by Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Routes of Administration, H1 2020
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2020
  • Number of Products by Top 10 Molecule Types, H1 2020
  • Number of Products by Stage and Top 10 Molecule Types, H1 2020
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Absynth Biologics Ltd
  • Acurx Pharmaceuticals LLC
  • Appili Therapeutics Inc
  • Artugen Therapeutics Ltd
  • Aviex Technologies LLC
  • AzurRx BioPharma Inc
  • Biomica
  • Botanix Pharmaceuticals Ltd
  • Boulos and Cooper Pharmaceuticals Pty Ltd
  • Cambimune Ltd
  • Chain Biotechnology Ltd
  • Crestone Inc
  • CSA Biotechnologies LLC
  • Daiichi Sankyo Co Ltd
  • Deinove SAS
  • Enterobiotix Ltd
  • Facile Therapeutics Inc
  • Finch Therapeutics Group
  • FloraSeq LLC
  • Fzata Inc
  • Galenus Therapeutics Inc
  • Gateway Pharmaceutical LLC
  • GlaxoSmithKline Plc
  • Immune Biosolutions Inc
  • ImmuneBiotech AB
  • ImmuniMed Inc
  • ImmunoBiology Ltd
  • Immuron Ltd
  • Inositec AG
  • Inovio Pharmaceuticals Inc
  • Inspyr Therapeutics Inc
  • Integrated BioTherapeutics Inc
  • Kaleido Biosciences Inc
  • KamTek Inc
  • KoBioLabs Inc
  • Locus Biosciences Inc
  • Mapp Biopharmaceutical Inc
  • Matrivax Research & Development Corp
  • Merck & Co Inc
  • MGB Biopharma Ltd
  • Microbiotica Ltd
  • Micropharm Ltd
  • Miyarisan Pharmaceutical Company Ltd
  • MyBiotics Pharma Ltd
  • Novabiotics Ltd
  • NovoBiotic Pharmaceuticals LLC
  • Nubiyota LLC
  • Oragenics Inc
  • Ostrich Pharma USA Inc
  • Otsuka Holdings Co Ltd
  • PanTheryx Inc
  • Pfizer Inc
  • Procarta Biosystems Ltd
  • Proxi Biotech IVS
  • Pylum Biosciences Inc
  • Q2 Pharma Ltd
  • QureTech Bio AB
  • Rebiotix Inc
  • Recursion Pharmaceuticals Inc
  • Rise Therapeutics LLC
  • Scioto Biosciences Inc
  • Seres Therapeutics Inc
  • Serometrix LLC
  • Servatus Ltd
  • Summit Therapeutics Plc
  • Symbiotic Health Inc
  • Synterica Inc
  • Synthetic Biologics Inc
  • The Broad Institute Inc
  • Valevia UK Ltd
  • Valneva SE
  • Vedanta Biosciences Inc
  • Vitality Biopharma Inc
  • XBiotech Inc
  • Xgene Pharmaceutical Inc
Note: Product cover images may vary from those shown
Adroll
adroll